Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gastrointestinal tumours, colorectal

405MO - Personalized circulating tumour DNA assay for the detection of minimal residual disease in CRC patients after resection of metastases


18 Sep 2020


Mini Oral - Gastrointestinal tumours, colorectal


Fotios Loupakis


Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270


F. Loupakis1, M. Derouazi2, S. Murgioni1, M.D. Rizzato1, S. Sharma3, D. Renner3, S. Shchegrova3, H. Sethi3, B. Zimmermann3, A. Aleshin3, M. Schirripa1, G. Munari4, A.P. Dei Tos4, S. Lonardi1, M. Fassan4

Author affiliations

  • 1 Department Of Oncology, IOV - Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 2 Na, Amal Therapeutics SA, 1205 - Geneva/CH
  • 3 R&d, Natera, 94070 - San Carlos/US
  • 4 Unit Of Surgical Pathology, Department Of Medicine, Dimed, University of Padua, 35128 - Padua/IT


Login to access the resources on OncologyPRO.

Abstract 405MO


Typically, most patients with mCRC are incurable. However, a minority of patients who undergo complete metastasectomy attain cure. In particular, up to 75% of oligometastatic CRC patients develop recurrence post-resection. Existing data in the oligometastatic setting has shown that the efficacy of postoperative adjuvant treatment is limited and is largely extrapolated from earlier stages. Establishing prognosis after oligometastatic resection is difficult and thus a need exists for a better prognostic marker. Circulating tumour DNA (ctDNA) has been shown to identify minimal residual disease (MRD) and the risk of recurrence in early-stage disease. In this study, we present the largest clinical experience of MRD testing in the oligometastatic setting.


Tumour tissue and serial plasma samples were collected from CRC patients undergoing resection of metastases with curative intent as part of the PREDATOR study. A personalized and tumour-informed multiplex PCR assay (Signatera™ bespoke mPCR NGS assay) was used for the detection and quantification of ctDNA for post-resection MRD assessment. The study evaluated the prognostic value of ctDNA correlating MRD status with clinical outcomes.


A total of 100 patients were analysed. Post-oligometastatic resection, adjuvant therapy was given to 38% of the patients at the discretion of the treating physician. Post-surgery, MRD-positivity was observed in 52% (52/100) of patients, of which 86.5% (45/52) eventually relapsed (HR: 4.6; 95%CI: 2.6-8.1; P<0.001). MRD-positive status was also associated with an inferior overall survival (HR: 22.0; 95%CI: 3.0-166.0, P=0.002). At the time of the analyses, in the MRD-negative arm, 98% of patients were alive compared to 57.7% in the MRD-positive arm. In the multivariate analysis, ctDNA status was the most significant prognostic factor associated with PFS (HR: 4.59, 95% CI: 2.51-8.4; P<0.001).


This study validates personalized ctDNA-based MRD status as the most significant biomarker for prognosis in patients with oligometastatic CRC. This biomarker may offer the clinical utility of guiding adjuvant treatment decisions in the oligometastatic setting and of informing future trial design.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Fotios Loupakis.




F. Loupakis: Advisory/Consultancy: Amal. S. Sharma, D. Renner, S. Shchegrova, H. Sethi, B. Zimmermann, A. Aleshin: Full/Part-time employment: Natera. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings